Aptevo Therapeutics Inc. (APVO) Return on equity 2016–2023
Aptevo Therapeutics Inc. (APVO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-96.9%FY2023 · since FY2016: -126.9% → -96.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -96.9% | -757.0 pp |
| FY2022 | 660.1% | +831.6 pp |
| FY2021 | -171.5% | -21.6 pp |
| FY2020 | -149.9% | -16.9 pp |
| FY2019 | -133.0% | -67.6 pp |
| FY2018 | -65.4% | -79.2 pp |
| FY2017 | 13.8% | +140.6 pp |
| FY2016 | -126.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More APVO financial trends
APVO RevenueAPVO Net incomeAPVO Net marginAPVO Gross profitAPVO Gross marginAPVO Operating incomeAPVO Operating marginAPVO Operating cash flowAPVO Free cash flowAPVO Capital expendituresAPVO Stock buybacksAPVO Dividends paidAPVO Total assetsAPVO Total liabilitiesAPVO Shareholders’ equityAPVO overview →